No Detail Found!

Expression, Prognosis, and Functional Analysis: KDM5B in Acute Myeloid Leukaemia (Non-M3)

Author(s)
Na Lu Department of Haematology, The First Affiliated Hospital of Guangxi Medical University, Guangxi, China;Department of Education, Guangxi Medical University, Guangxi Zhuang Autonomous Region, Guangxi, China
Xiaoke Huang Department of Haematology, The First Affiliated Hospital of Guangxi Medical University, Guangxi, China;Department of Education, Guangxi Medical University, Guangxi Zhuang Autonomous Region, Guangxi, China
Xiaolin Liang Department of Education, Guangxi Medical University,Guangxi Zhuang Autonomous Region, Guangxi,China
Qin Li Department of Haematology, The First A liated Hospital of Guangxi Medical University,Guangxi,China
Yuling Xu Department of Haematology, The First Affiliated Hospital of Guangxi Medical University, Guangxi, China;Department of Education, Guangxi Medical University, Guangxi Zhuang Autonomous Region, Guangxi, China
Zhenfang Liu Department of Haematology, The First Affiliated Hospital of Guangxi Medical University, Guangxi, China;Department of Education, Guangxi Medical University, Guangxi Zhuang Autonomous Region, Guangxi, China
Abstract
To investigate the value of Lysine Demethylase 5B (KDM5B) in the prognosis and immunity of acute myeloid leukaemia (AML). Study Design: A case-control study. Place and Duration of the Study: Department of Haematology, The First A liated Hospital of Guangxi Medical University, Nanning, Guangxi, China, from 2013 to 2024. Methodology: Bioinformatic methods were used to compare the expression of KDM5B between 135 individuals with AML and 70 individuals without AML in the TCGA database. In order to con rm the ndings, bone marrow specimens underwent real-time polymerase chain reaction analysis by the Mann-Whitney U test. A comprehensive assessment was conducted to explore the interplay among KDM5B expression levels, clinical pro les, and the overall survival prognosis in AML patients. Furthermore, the underlying mechanism of KDM5B in AML pathogenesis was delved into utilising GSEA. To assess the impact of KDM5B expression on the immune landscape within tumours, the ESTIMATE and CIBERSORT computational methodologies were employed to evaluate its role in tumour immune in ltration. Results: KDM5B expression was notably increased in AML patients and linked to a poor prognosis. KDM5B expression was correlated with NPM1 mutation in bone marrow samples. Additionally, high KDM5B expression was a poor prognostic factor for overall survival. GSEA showed that high KDM5B expression was related to the immune system.Analysis of immune in ltration revealed a correlation between elevated KDM5B expression and decreased stromal and immune scores, accompanied by altered in ltration patterns of diverse immune cell types. Furthermore, immune checkpoint markers were correlated with low KDM5B expression. Conclusion: KDM5B is highly expressed in AML andcorrelates with poor prognosis. KDM5B may be involved in AML by a ecting the tumour micro-environment, thus being a potential biological target in AML.
Publication Details
Page(s) 426-435
Published Journal: Journal of the College of Physicians and Surgeons Pakistan, Volume: 35, Issue: 04, Year: 2025

Request the full text from PASTIC

Keywords
Acute myeloid leukaemia, Prognostic factor, KDM5B, Immune in ltration
References
Short NJ,Rytting ME,Cortes JE .2018 .Acute myeloid leukaemia. Lancet, 6736(18) : 31041-9.
Bhansali RS,Pratz KW,Lai C .2023 .Recent advances in targeted therapies in acute myeloid leukaemia. J Hematol Oncol, 10(1) : 29.
Kooistra SM,Helin K. .2012 .Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol, 10(5) : 297-311.
Guo JC,Liu Z,Yang YJ,Guo M,Zhang JQ,Zheng JF .2021 .Kdm5b promotes self-renewal of hepatocellular carcinoma cells through the microrna-448-mediated Ythdf3/Itga6 axis. J Cell Mol Med, 10(13) : 5949-62.
Liu B,Kumar R,Chao HP,Mehmood R,Ji Y,Tracz A .2020 .Evidence for context-dependent functions of Kdm5b in prostate development and prostate cancer. Oncotarget, 10(46) : 4243-52.
.2021 .Systemic pro ling of Kdm5 subfamily signature in non-small-cell lung cancer. Int J Gen Med, 10 : 7259-75.
Huang D,Qiu Y,Li G,Liu C,She L,Zhang D .2018 .Kdm5b overexpression predicts a poor prognosis in patients with squamous cell carcinoma of the head and neck. J Cancer, 10(1) : 198-204.
Shokri G,Doudi S,Fathi-Roudsari M,Kouhkan F,Sanati MH .2018 .Targeting histone demethylases Kdm5a and Kdm5b in aml cancer cells: A comparative view. Leuk Res, 02 : 105-11.
Huang J,Jin S,Guo R,Wu W,Yang C,Qin Y .2024 .Histone lysine demethylase Kdm5b facilitates proliferation and suppresses apoptosis in human acute myeloid leukaemia cells through the mir-140-3p/Bcl2 axis. RNA, 10(4) : 435-47.
Ren Z,Kim A,Huang YT,Pi WC,Gong W,Yu X . .A Prc2- Kdm5b axis sustains tumourigenicity of acute myeloid leukaemia. Proc Nat Acad Sci, 10(9) : .
Chan LH,Yan Q.,Awakening Q. .2022 .Kdm5b to defeat leukaemia. Proc Nat Acad Sci USA, 10(13) : .
Montano MM,Yeh IJ,Chen Y,Hernandez C,Kiselar JG,de la Fuente M .2019 .Inhibition of the histone demethylase, Kdm5b, directly induces re-expression of tumour suppressor protein hexim1 in cancer cells. Breast Cancer Res, 10(1) : 138.
Daver N,Manero GG,Basu S,Boddu PC,Alfayez M,Cortes JE .2019 .E cacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukaemia: A nonrandomized, open-label, phase Ii study. Cancer Discov, 18(3) : 2159-8290.
Bindea G,Mlecnik B,Tosolini M,Kirilovsky A,Waldner M,Obenauf AC .2013 .Spatiotemporal dynamics of intratumoural immune cells reveal the immune landscape in human cancer. Immunity, 10(4) : 782-95.
Thorsson V,Gibbs DL,Brown SD,Wolf D,Bortone DS,Ou Yang TH .2018 .The immune landscape of cancer. Immunity, 03(4) : 812-30.
Danilova L,Ho WJ,Zhu Q,Vithayathil T,De Acosta AJ,Azad NS .2019 .Programmed Cell death ligand-1 (Pd-L1) and Cd8 expression pro ling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival. Cancer Immunol Res, 18(6) : 2326-6066.
Hanahan D,Coussens LM .2012 .Accessories to the crime: Functions of cells recruited to the tumour micro-environment. Cancer cell, 02(3) : 309-22.
Ganesan S,Mathews V,Vyas N. .2022 .Micro-environment and drug resistance in acute myeloid leukemia: Do we know enough?. Int J Cancer, 10(9) : 1401-11.
Vago L,Gojo I. .2020 .Immune escape and immunotherapy of acute myeloid leukaemia. J Clin Invest, 10(4) : 1552-64.
Li X,Li J,Liu Y,Sun L,Tai Q,Gao S .2023 .Inhibition of Kdm5b participates in immune microenvironment remodeling in pancreatic cancer by inducing sting expression. Cytokine, 156451 : 156451.
Sauerer T,Velazquez GF,Schmid C .2023 .Relapse of acute myeloid leukaemia after allogeneic stem cell transplantation: Immune escape mechanisms and current implications for therapy. Mol Cancer, 10(1) : 180.
Tal SG,Rothenberg ME,Munitz A .2022 .Eosinophil-lymphocyte interactions in the tumour microenvironment and cancer immunotherapy. Nat Immunol, 10(9) : 1309-16.
Fitz-James MH,Cavalli G .2022 .Molecular mechanisms of transgenerational epigenetic inheritance. Nat Rev Genet, 10(6) : 325-41.
Zhang SM,Cai WL,Liu X,Thakral D,Luo J,Chan LH .2021 .Kdm5b promotes immune evasion by recruiting setdb1 to silence retroelements. Nature, 10(7882) : 682-7.
Momparler RL,Cote S,Momparler LF .2021 .5(2):7. Epigenomes, 10 : .
0

Citations

0

Downloads

53

Views